tetano
Editor, Senior Moderator
Immunol Cell Biol. 2020 Jan 8. doi: 10.1111/imcb.12312. [Epub ahead of print] [h=1]The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens.[/h]
Vanderven HA[SUP]1,[/SUP][SUP]2[/SUP], Kent SJ[SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h] 1 Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Queensland, Australia. 2 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia. 3 Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia. 4 Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University.
[h=3]Abstract[/h] In recent years, there has been a renewed interest in utilising antibody Fc functions to prevent and control viral infections. The protective and therapeutic potential of Fc-mediated antibody functions have been assessed for some clinically important human viruses, including human immunodeficiency virus (HIV), haemorrhagic fever viruses and influenza virus. There is mounting evidence that influenza-specific antibodies with Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), can aid in the clearance of influenza virus infection. Recent influenza challenge studies and intravenous immunoglobulin G (IVIG) therapy studies in humans suggest a protective role for Fc effector functions in vivo. Broadly-reactive influenza antibodies with Fc-mediated functions are prevalent in the human population and could inform the development of a universally protective influenza vaccine or therapy. In this review, we explore the utility of antibodies with Fc-mediated effector functions against viral infections with emphasis on influenza virus.
? 2020 Australian and New Zealand Society for Immunology Inc.
[h=4]KEYWORDS:[/h] Antibodies; Fc receptors; antibody-dependent cellular cytotoxicity (ADCC); antibody-dependent phagocytosis (ADP); influenza virus; natural killer (NK) cells
PMID: 31914207 DOI: 10.1111/imcb.12312
Vanderven HA[SUP]1,[/SUP][SUP]2[/SUP], Kent SJ[SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h] 1 Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Queensland, Australia. 2 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria, Australia. 3 Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia. 4 Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University.
[h=3]Abstract[/h] In recent years, there has been a renewed interest in utilising antibody Fc functions to prevent and control viral infections. The protective and therapeutic potential of Fc-mediated antibody functions have been assessed for some clinically important human viruses, including human immunodeficiency virus (HIV), haemorrhagic fever viruses and influenza virus. There is mounting evidence that influenza-specific antibodies with Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), can aid in the clearance of influenza virus infection. Recent influenza challenge studies and intravenous immunoglobulin G (IVIG) therapy studies in humans suggest a protective role for Fc effector functions in vivo. Broadly-reactive influenza antibodies with Fc-mediated functions are prevalent in the human population and could inform the development of a universally protective influenza vaccine or therapy. In this review, we explore the utility of antibodies with Fc-mediated effector functions against viral infections with emphasis on influenza virus.
? 2020 Australian and New Zealand Society for Immunology Inc.
[h=4]KEYWORDS:[/h] Antibodies; Fc receptors; antibody-dependent cellular cytotoxicity (ADCC); antibody-dependent phagocytosis (ADP); influenza virus; natural killer (NK) cells
PMID: 31914207 DOI: 10.1111/imcb.12312